Brief: Innovate Biopharmaceuticals Reports Financing To Initiate The First Phase 3 Clinical Trial In Celiac Disease

9 Meters Biopharma

19/03/2019 12:14

March 19 (Reuters) - Innovate Biopharmaceuticals Inc
 INNT.O :
    * INNOVATE BIOPHARMACEUTICALS REPORTS FINANCING TO INITIATE
THE
FIRST PHASE 3 CLINICAL TRIAL IN CELIAC DISEASE, FISCAL YEAR 2018
EARNINGS AND KEY CORPORATE HIGHLIGHTS
    * INNOVATE BIOPHARMACEUTICALS INC - CONTINUED LAUNCH
ACTIVITIES
FOR START OF FIRST PHASE 3 CELIAC DISEASE TRIAL, EXPECTED TO
START Q2 2019
    * INNOVATE BIOPHARMACEUTICALS INC - INNOVATE CLOSES AN
EQUITY
FINANCING WITH GROSS PROCEEDS OF $9.7 MILLION
    * INNOVATE BIOPHARMACEUTICALS - AT DECEMBER 31, 2018, HAD
$5.7
MILLION IN CASH AND CASH EQUIVALENTS COMPARED TO $0.4 MILLION AT
DECEMBER 31, 2017.
    * INNOVATE BIOPHARMA - TO USE NET PROCEEDS TO INITIATE ITS
FIRST
PHASE 3 REGISTRATION TRIAL OF LARAZOTIDE ACETATE, OR INN-202,
FOR CELIAC DISEASE

Source text for Eikon:  ID:nGNX3QrTfF 
Further company coverage:  INNT.O 

 ((Reuters.Briefs@thomsonreuters.com;))